The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma.
 
Alain Patrick Algazi
Research Funding - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck; OncoSec
 
Megan Othus
No Relationships to Disclose
 
Adil Daud
Stock and Other Ownership Interests - Oncosec
Consulting or Advisory Role - GlaxoSmithKline; Merck; Oncosec
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst)
 
Janice M. Mehnert
Consulting or Advisory Role - Amgen/Dompé (Inst)
Research Funding - Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); polynoma (Inst); Sanofi (Inst)
Other Relationship - Amgen
 
Christopher D. Lao
No Relationships to Disclose
 
Ragini Reiney Kudchadkar
No Relationships to Disclose
 
Kenneth F. Grossmann
Consulting or Advisory Role - Roche/Genentech
 
Roger Lo
Research Funding - GlaxoSmithKline
 
James Moon
No Relationships to Disclose
 
John M. Kirkwood
No Relationships to Disclose
 
Antoni Ribas
Stock and Other Ownership Interests - Compugen; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Merck Sharp & Dohme (Inst)